Pub Date : 2025-06-26DOI: 10.1038/s41391-025-00993-6
Hailin Yang, Xuhen Liu, Ju Guo
{"title":"Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions","authors":"Hailin Yang, Xuhen Liu, Ju Guo","doi":"10.1038/s41391-025-00993-6","DOIUrl":"10.1038/s41391-025-00993-6","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"28 4","pages":"1019-1019"},"PeriodicalIF":5.8,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-21DOI: 10.1038/s41391-025-00994-5
Mayuko Kanayama, Emeline Colomba, Yusra Shao, Sarah M Nielsen, Edward D Esplin, Changxue Lu, William B Isaacs, John C Henegan, Elisabeth I Heath, Jun Luo, Régine Marlin, Emmanuel S Antonarakis
Background: Recently, a germline HOXB13 variant, X285K was identified as a risk factor for prostate cancer in men of African ancestry. While this variant is likely associated with more aggressive prostate cancer, there has not yet been an in-depth clinical description of individual patients carrying this variant and their response to systemic therapies.
Methods: We studied six cases of germline X285K carriers with metastatic hormone-sensitive prostate cancer to characterize their hormonal sensitivity or resistance.
Conclusions: Longitudinal outcome analysis indicates that patients carrying X285K generally show favorable responses to therapies targeting the androgen receptor (AR), a finding that requires confirmation.
{"title":"Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant.","authors":"Mayuko Kanayama, Emeline Colomba, Yusra Shao, Sarah M Nielsen, Edward D Esplin, Changxue Lu, William B Isaacs, John C Henegan, Elisabeth I Heath, Jun Luo, Régine Marlin, Emmanuel S Antonarakis","doi":"10.1038/s41391-025-00994-5","DOIUrl":"10.1038/s41391-025-00994-5","url":null,"abstract":"<p><strong>Background: </strong>Recently, a germline HOXB13 variant, X285K was identified as a risk factor for prostate cancer in men of African ancestry. While this variant is likely associated with more aggressive prostate cancer, there has not yet been an in-depth clinical description of individual patients carrying this variant and their response to systemic therapies.</p><p><strong>Methods: </strong>We studied six cases of germline X285K carriers with metastatic hormone-sensitive prostate cancer to characterize their hormonal sensitivity or resistance.</p><p><strong>Conclusions: </strong>Longitudinal outcome analysis indicates that patients carrying X285K generally show favorable responses to therapies targeting the androgen receptor (AR), a finding that requires confirmation.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-12DOI: 10.1038/s41391-025-00988-3
Kamran Abbasi, Parveen Ali, Virginia Barbour, Marion Birch, Inga Blum, Peter Doherty, Andy Haines, Ira Helfand, Richard Horton, Kati Juva, Jose F. Lapena Jr, Robert Mash, Olga Mironova, Arun Mitra, Carlos Monteiro, Elena N. Naumova, David Onazi, Tilman Ruff, Peush Sahni, James Tumwine, Carlos Umaña, Paul Yonga, Chris Zielinski
{"title":"Ending nuclear weapons, before they end us","authors":"Kamran Abbasi, Parveen Ali, Virginia Barbour, Marion Birch, Inga Blum, Peter Doherty, Andy Haines, Ira Helfand, Richard Horton, Kati Juva, Jose F. Lapena Jr, Robert Mash, Olga Mironova, Arun Mitra, Carlos Monteiro, Elena N. Naumova, David Onazi, Tilman Ruff, Peush Sahni, James Tumwine, Carlos Umaña, Paul Yonga, Chris Zielinski","doi":"10.1038/s41391-025-00988-3","DOIUrl":"10.1038/s41391-025-00988-3","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 1","pages":"1-2"},"PeriodicalIF":5.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41391-025-00988-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-10DOI: 10.1038/s41391-025-00989-2
M. J. van Harten, S. Remmers, R. C. N. van den Bergh, M. J. Roobol
{"title":"Prostate cancer screening in Europe: future directions and perspectives","authors":"M. J. van Harten, S. Remmers, R. C. N. van den Bergh, M. J. Roobol","doi":"10.1038/s41391-025-00989-2","DOIUrl":"10.1038/s41391-025-00989-2","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 1","pages":"100-102"},"PeriodicalIF":5.8,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-04DOI: 10.1038/s41391-025-00992-7
Fabian Falkenbach, Lukas Hohenhorst, Mykyta Kachanov, Tim Inderhees, Dirk Beyersdorff, Daniel Koehler, Sami-Ramzi Leyh-Bannurah, Tobias Maurer, Markus Graefen, Lars Budäus
{"title":"Perspective transition from transrectal to transperineal MRI-fusion biopsy under local anesthesia - the institutional TREXIT learning curve of the new gold standard.","authors":"Fabian Falkenbach, Lukas Hohenhorst, Mykyta Kachanov, Tim Inderhees, Dirk Beyersdorff, Daniel Koehler, Sami-Ramzi Leyh-Bannurah, Tobias Maurer, Markus Graefen, Lars Budäus","doi":"10.1038/s41391-025-00992-7","DOIUrl":"https://doi.org/10.1038/s41391-025-00992-7","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-02DOI: 10.1038/s41391-025-00987-4
Leonardo Quarta, Armando Stabile, Francesco Pellegrino, Pietro Scilipoti, Mattia Longoni, Donato Cannoletta, Paolo Zaurito, Alfonso Santangelo, Alessandro Viti, Francesco Barletta, Simone Scuderi, Riccardo Leni, Antony Pellegrino, Elio Mazzone, Luigi Nocera, Giorgio Brembilla, Francesco De Cobelli, Robert Jeffrey Karnes, Morgan Rouprêt, Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti
The use of prostate-specific antigen density (PSAd) in combination with multiparametric magnetic resonance imaging (mpMRI) of the prostate can improve accuracy of the prostate cancer (PCa) diagnostic pathway. However, it is not clear whether the performance characteristics of PSAd vary according to the index lesion location (ILL) on mpMRI. Overall, 2140 patients with positive mpMRI (prostate imaging reporting and data system [PI-RADS] ≥ 3) underwent mpMRI-targeted biopsy (TBx) plus systematic biopsy (SBx) at three tertiary referral centers. Multivariable logistic regression analysis (MVA) tested the interaction between PSAd and ILL (peripheral zone [PZ] vs transitional zone [TZ]) in predicting clinically significant PCa (csPCa, defined as ISUP grade group ≥2) at TBx. Non-parametric locally weighted scatterplots smoothing approach (LOWESS) explored the relationship between PSAd and csPCa according to ILL and stratifying by PI-RADS score. Median PSA was 6.7 ng/ml. ILL was PZ and TZ in 77% and 23% patients, respectively. Overall, 39% of csPCa cases were diagnosed at TBx. The association between PSAd and csPCa varied according to ILL (interaction test: p < 0.01). In patients with PI-RADS 3 lesions, csPCa incidence was <10% in cases of PSAd values < 0.05 ng/ml/ml and <0.13 ng/ml/ml for PZ and TZ lesions, respectively. Differently, in patients with PI-RADS ≥ 4, csPCa incidence was ≥20% regardless of PSAd value and ILL. The likelihood of detecting csPCa in patients with PI-RADS 3 lesions is influenced by the combination of PSAd and ILL. Specifically, patients with PZ and TZ PI-RADS 3 lesions have an increased risk of csPCa for PSAd values ≥ 0.05 ng/ml/ml and ≥0.13 ng/ml/ml, respectively. Conversely, patients with PI-RADS ≥ 4 lesions have a non-negligible risk of csPCa regardless of PSAd and ILL.
{"title":"Tailored use of PSA density according to multiparametric MRI index lesion location: results of a large, multi-institutional series","authors":"Leonardo Quarta, Armando Stabile, Francesco Pellegrino, Pietro Scilipoti, Mattia Longoni, Donato Cannoletta, Paolo Zaurito, Alfonso Santangelo, Alessandro Viti, Francesco Barletta, Simone Scuderi, Riccardo Leni, Antony Pellegrino, Elio Mazzone, Luigi Nocera, Giorgio Brembilla, Francesco De Cobelli, Robert Jeffrey Karnes, Morgan Rouprêt, Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti","doi":"10.1038/s41391-025-00987-4","DOIUrl":"10.1038/s41391-025-00987-4","url":null,"abstract":"The use of prostate-specific antigen density (PSAd) in combination with multiparametric magnetic resonance imaging (mpMRI) of the prostate can improve accuracy of the prostate cancer (PCa) diagnostic pathway. However, it is not clear whether the performance characteristics of PSAd vary according to the index lesion location (ILL) on mpMRI. Overall, 2140 patients with positive mpMRI (prostate imaging reporting and data system [PI-RADS] ≥ 3) underwent mpMRI-targeted biopsy (TBx) plus systematic biopsy (SBx) at three tertiary referral centers. Multivariable logistic regression analysis (MVA) tested the interaction between PSAd and ILL (peripheral zone [PZ] vs transitional zone [TZ]) in predicting clinically significant PCa (csPCa, defined as ISUP grade group ≥2) at TBx. Non-parametric locally weighted scatterplots smoothing approach (LOWESS) explored the relationship between PSAd and csPCa according to ILL and stratifying by PI-RADS score. Median PSA was 6.7 ng/ml. ILL was PZ and TZ in 77% and 23% patients, respectively. Overall, 39% of csPCa cases were diagnosed at TBx. The association between PSAd and csPCa varied according to ILL (interaction test: p < 0.01). In patients with PI-RADS 3 lesions, csPCa incidence was <10% in cases of PSAd values < 0.05 ng/ml/ml and <0.13 ng/ml/ml for PZ and TZ lesions, respectively. Differently, in patients with PI-RADS ≥ 4, csPCa incidence was ≥20% regardless of PSAd value and ILL. The likelihood of detecting csPCa in patients with PI-RADS 3 lesions is influenced by the combination of PSAd and ILL. Specifically, patients with PZ and TZ PI-RADS 3 lesions have an increased risk of csPCa for PSAd values ≥ 0.05 ng/ml/ml and ≥0.13 ng/ml/ml, respectively. Conversely, patients with PI-RADS ≥ 4 lesions have a non-negligible risk of csPCa regardless of PSAd and ILL.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 1","pages":"111-115"},"PeriodicalIF":5.8,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-02DOI: 10.1038/s41391-025-00990-9
Ryan C Au, Pocharapong Jenjitranant, Derek W Cool, Jonathan Izawa, Brant Inman, Aaron Ward, Joseph L Chin
{"title":"Artificial intelligence may enhance the role of magnetic resonance imaging in prostate cancer focal therapy.","authors":"Ryan C Au, Pocharapong Jenjitranant, Derek W Cool, Jonathan Izawa, Brant Inman, Aaron Ward, Joseph L Chin","doi":"10.1038/s41391-025-00990-9","DOIUrl":"https://doi.org/10.1038/s41391-025-00990-9","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-28DOI: 10.1038/s41391-025-00991-8
Yuekun Fang, Shengyi Chen, Cheng Bin
{"title":"Toward a holistic understanding of Metformin's Role in oncology: responding to methodological limitations and enhancing translational relevance.","authors":"Yuekun Fang, Shengyi Chen, Cheng Bin","doi":"10.1038/s41391-025-00991-8","DOIUrl":"https://doi.org/10.1038/s41391-025-00991-8","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To assess long-term survival in a “STAMPEDE-like” cohort of high-risk locally advanced prostate cancer, staged with PSMA PET-CT, treated with hypofractionated radiotherapy (RT) and long-term androgen deprivation therapy (LT-ADT) without abiraterone. Patients with non-metastatic prostate cancer fulfilling “STAMPEDE high-risk” criteria, staged with PSMA PET-CT, treated with external beam RT from 2016 to 2021 were included. RT dose was >74 Gy equivalent to prostate with LT-ADT ≥ 2 years. We analysed metastatic-free survival (MFS), prostate cancer specific survival (PCSS) and overall survival (OS) using Kaplan-Meier method. 170 patients were eligible, treated with hypofractionated RT with median prostate 2Gy-equivalent dose of 82 Gy. About one-third were node-positive and treated with whole pelvic RT. Over median follow up of 65 months, 6-years MFS, PCSS and OS were 80.7%, 95.8% and 94.4% respectively. On multivariate analysis, Gleason score and nodal stage showed significant association with MFS. For PSMA-PETCT staged high risk prostate cancer, appropriately intensified local treatment could be complementary or an alternative to systemic intensification in selected patients.
{"title":"Abiraterone for “STAMPEDE-Like” cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?","authors":"Vedang Murthy, Asesh Samanta, Priyamvada Maitre, Prashant Nayak, Pallavi Singh, Archi Agrawal, Amit Joshi, Gagan Prakash","doi":"10.1038/s41391-025-00983-8","DOIUrl":"10.1038/s41391-025-00983-8","url":null,"abstract":"To assess long-term survival in a “STAMPEDE-like” cohort of high-risk locally advanced prostate cancer, staged with PSMA PET-CT, treated with hypofractionated radiotherapy (RT) and long-term androgen deprivation therapy (LT-ADT) without abiraterone. Patients with non-metastatic prostate cancer fulfilling “STAMPEDE high-risk” criteria, staged with PSMA PET-CT, treated with external beam RT from 2016 to 2021 were included. RT dose was >74 Gy equivalent to prostate with LT-ADT ≥ 2 years. We analysed metastatic-free survival (MFS), prostate cancer specific survival (PCSS) and overall survival (OS) using Kaplan-Meier method. 170 patients were eligible, treated with hypofractionated RT with median prostate 2Gy-equivalent dose of 82 Gy. About one-third were node-positive and treated with whole pelvic RT. Over median follow up of 65 months, 6-years MFS, PCSS and OS were 80.7%, 95.8% and 94.4% respectively. On multivariate analysis, Gleason score and nodal stage showed significant association with MFS. For PSMA-PETCT staged high risk prostate cancer, appropriately intensified local treatment could be complementary or an alternative to systemic intensification in selected patients.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"28 4","pages":"985-988"},"PeriodicalIF":5.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41391-025-00983-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-22DOI: 10.1038/s41391-025-00985-6
Steven A. Kaplan, Dean S. Elterman
{"title":"New BPH therapy classification: what really FITs?","authors":"Steven A. Kaplan, Dean S. Elterman","doi":"10.1038/s41391-025-00985-6","DOIUrl":"10.1038/s41391-025-00985-6","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 1","pages":"98-99"},"PeriodicalIF":5.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号